|15 nM||20 nM||200 nM|
|In vitro||DMSO||6 mg/mL heating (24.06 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||40.11 mL||200.56 mL||401.12 mL|
|0.5 mM||8.02 mL||40.11 mL||80.22 mL|
|1 mM||4.01 mL||20.06 mL||40.11 mL|
|5 mM||0.8 mL||4.01 mL||8.02 mL|
*The above data is based on the productmolecular weight 249.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
PHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM, less potent to CDK3 and little active to CD…
Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia…
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.